Comparative Pharmacology
Head-to-head clinical analysis: LOMUSTINE versus ZEPZELCA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOMUSTINE versus ZEPZELCA.
LOMUSTINE vs ZEPZELCA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Alkylating agent that crosslinks DNA, inhibits DNA synthesis, and produces interstrand crosslinks via chloroethyl carbonium ion formation. Also has carbamoylating activity.
Lurbinectedin is a selective inhibitor of oncogenic transcription. It binds to the minor groove of DNA, inhibiting the activity of RNA polymerase II and promoting its degradation, thereby reducing transcription of certain oncogenes and inducing apoptosis in cancer cells.
130 mg/m² orally as a single dose every 6 weeks; subsequent doses adjusted based on hematologic response.
3.24 mg/m2 intravenously over 60 minutes every 21 days until disease progression or unacceptable toxicity.
None Documented
None Documented
Clinical Note
moderateLomustine + Digoxin
"Lomustine may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateLomustine + Digitoxin
"Lomustine may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateLomustine + Deslanoside
"Lomustine may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateLomustine + Acetyldigitoxin
"Lomustine may decrease the cardiotoxic activities of Acetyldigitoxin."
Biphasic: initial half-life ~6 hours; terminal half-life ~16-48 hours (mean 24 hours). Metabolites have prolonged half-life up to 72 hours. Clinical context: accumulation with repeated dosing, requiring 6-week intervals.
Terminal elimination half-life is approximately 7-9 hours in patients with normal hepatic function, supporting once-daily dosing.
Renal excretion approximately 50% (as metabolites), biliary/fecal excretion approximately 20%; remainder unaccounted, likely metabolized.
Primarily hepatic metabolism, with biliary/fecal excretion as the major route (approximately 60-80% of the administered dose). Renal excretion accounts for <20% of the dose as unchanged drug and metabolites.
Category D/X
Category C
Alkylating Agent
Alkylating Agent